Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288855 | 1.00 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10ACP3NR4A1 | |
| SCHEMBL146376 | 1.00 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10ACP3NR4A1 | |
| SCHEMBL29608063 | 1.00 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10ACP3NR4A1 | |
| SCHEMBL4963997 | 0.90 | ALDH1A1 (0.45) | KDM4EALDH1A1HSD17B10ACP3NR4A1 | |
| SCHEMBL7287554 | 0.85 | KDM4E (0.53) | KDM4EALDH1A1HSD17B10ACP3NR4A1 | |
| SCHEMBL27165013 | 0.85 | KDM4E (0.39) | KDM4EALDH1A1HSD17B10ACP3KIF11 | |
| SCHEMBL28252994 | 0.83 | KIF11 (0.49) | KDM4EALDH1A1KIF11TDP1MEN1 | |
| Norleucine SCHEMBL28063292 | 0.82 | KIF11 (0.51) | KDM4EALDH1A1HSD17B10KIF11TDP1 | |
| SCHEMBL27575255 | 0.82 | KIF11 (0.40) | KDM4EALDH1A1HSD17B10ACP3KIF11 | |
| SCHEMBL4678773 | 0.81 | KDM4E (0.53) | KDM4EALDH1A1HSD17B10ACP3NR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1845 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119868594-A | Method for radiolabelling GRPR antagonist and kit thereof | 诺华股份有限公司 | 2025-04-25 | — | — | CN | claimed |
| US-20230321287-A1 | RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | claimed |
| EP-4031194-A1 | METHODS FOR RADIOLABELLING GRPR ANTAGONISTS AND THEIR KITS | Novartis AG (CH) | 2022-07-27 | — | — | EP | claimed |
| CN-114728087-A | Method for radiolabeling GRPR antagonist and kit thereof | 诺华股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-114728089-A | Radiolabeled GRPR antagonists as theranostic agents | 诺华股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-114432423-A | NF for treating diseases and disorderskInhibitors of B activity | 拉金德拉·萨哈伊·巴特纳格尔 | 2022-05-06 | — | — | CN | claimed |
| US-20220008566-A1 | Pharmaceutical Composition Comprising a Radiolabeled GRPR Antagonist and a Surfactant | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-01-13 | — | — | US | claimed |
| CN-113195005-A | Pharmaceutical compositions comprising radiolabeled GRPR antagonist and surfactant | 国际先进加速器应用公司 | 2021-07-30 | — | — | CN | claimed |
| US-20210121518-A1 | HER2-TARGETED PEPTIDOMIMETICS GRAFTED ONTO MULTICYCLIC PEPTIDE SCAFFOLDS AND METHODS AND USES | LaRose Industries, LLC | 2021-04-29 | — | — | US | claimed |
| WO-2021053040-A1 | METHODS FOR RADIOLABELLING GRPR ANTAGONISTS AND THEIR KITS | Advanced Accelerator Applications (Italy) Srl (IT) | 2021-03-25 | — | — | WO | claimed |
| US-5256645-A | Renin inhibitors; hypotensive agents | HOFFMANN-LA ROCHE INC. (US) | 1993-10-26 | — | — | US | claimed |
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | claimed |
| US-5210075-A | Interleukin 6 antagonist peptides | TANABE SEIYAKU CO., LTD. (JP) | 1993-05-11 | — | — | US | claimed |
| CN-1068333-A | Has hydrazine analog derivative of pharmacologically active and preparation method thereof | CIBA GEIGY AG (CH) | 1993-01-27 | — | — | CN | claimed |
| US-5140011-A | Hypotensive agents | HOFFMANN-LA ROCHE, INC. (US) | 1992-08-18 | — | — | US | claimed |
| US-5134123-A | Renin enzyme inhibitors for cardiovascular disorders and high blood pressure | HOFFMAN-LA ROCHE INC. (US) | 1992-07-28 | — | — | US | claimed |
| EP-0422937-A1 | Fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1991-04-17 | — | — | EP | claimed |
| EP-0410541-A1 | Fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1991-01-30 | — | — | EP | claimed |
| EP-0309297-A2 | Therapeutic peptides | The Administrators of The Tulane Educational Fund (US) | 1989-03-29 | — | — | EP | claimed |
| EP-0162414-A2 | Amphipathic peptides and pharmaceutical compositions containing same | Research Corporation (US) | 1985-11-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008566-A1 | Pharmaceutical Composition Comprising a Radiolabeled GRPR Antagonist and a Surfactant | GRPR, GIPR, SCTR | KDM4E 4858/4885ALDH1A1 4771/4885HSD17B10 4293/4885 |
| US-20230321287-A1 | RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC | GRPR, GIPR, SCTR | KDM4E 4844/4885ALDH1A1 4782/4885HSD17B10 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.